Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration

Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine

Volumn 53, Issue 6, 2006, Pages 300-304

  Carceles C M ^a   Serrano, J M ^a,b   Marin P ^a   Escudero, E ^a   Fernandez Varon E ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION ROUTE; FEMALE; FLUORESCENCE; GEL; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; RABBIT; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; AREA UNDER CURVE; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG ADMINISTRATION ROUTES; FEMALE; FLUORESCENCE; GELS; HALF-LIFE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; QUINOLINES; RABBITS;

ORYCTOLAGUS CUNICULUS; STAPHYLOCOCCUS AUREUS;

EID: 33746330443     PISSN: 0931184X     EISSN: 14390442     Source Type: Journal    
DOI: 10.1111/j.1439-0442.2006.00827.x     Document Type: Article

References (22)

1. Abd El-Aty, A. M., A. Goudah, M. Ismail, S. M. Mounir, and M. Shimoda, 2005: Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of dicural. Vet. Res. Commun. 29, 297-304.
2. Aliabadi, F. S., and P. Lees, 2001: Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. Am. J. Vet. Res. 62, 1979-1989.
3. Broome, R. L., D. L. Brooks, J. G. Babish, D. D. Copeland, and G. M. Conzelman, 1991: Pharmacokinetic properties of enrofloxacin in rabbits. Am. J. Vet. Res. 52, 1835-1841.
4. Brown, S. A., 1996: Fluorquinolones in animal health. J. Vet. Pharmacol. Ther. 19, 1-14.
5. Cabanes, A., M. Arboix, J. M. García-Antón, and F. Reig, 1992: Pharmacokinetics of enrofloxacin after intravenous and intramuscular injection in rabbits. Am. J. Vet. Res. 53, 2090-2093.
6. Cester, C., M. Schneider, and P. L. Toutain, 1996: Comparative kinetics of two orally administered fluoroquinolones in dog: enrofloxacin versus marbofloxacin. Rev. Med. Vet. 147, 703-716.
7. Drlica, K., and X. Zhao, 1997: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61, 377-392.
8. Drusano, G. L., D. E. Johnson, M. Rosen, and H. Standiford, 1993: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37, 483-490.
9. Fernández-Varón, E., M. J. Bovaira, A. Espuny, E. Escudero, D. Vancraeynest, and C. M. Cárceles, 2005: Pharmacokinetic- pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. J. Vet. Pharmacol. Ther. 27, 57-60.
10. Gardner, S. Y., J. L. Davis, S. L. Jones, D. H. Lafevers, M. S. Hoskins, E. M. Mcarver, and M. G. Papich, 2004: Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing. J. Vet. Pharmacol. Ther. 27, 57-60.
11. Johnston, T. P., M. A. Punjabi, and C. Froelich, 1992: Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm. Res. 9, 425-434.
12. Lode, H., K. Borner, and P. Koeppe, 1998: Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 27, 33-39.
13. Pec, E. A., Z. Wout, and T. P. Johnston, 1996: Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J. Pharm. Sci. 81, 626-630.
14. Powers, J., 1990: Statistical analysis of pharmacokinetic data. J. Vet. Pharmacol. Ther. 13, 113-120.
15. Prescott, J. F., J. D. Baggot, and R. D. Walker, 2000: Antimicrobial therapy in veterinary medicine, 3rd edn, pp. 57. Iowa State Press, Ames, IA.
16. Ricci, E. J., L. O. Lunardi, D. M. A. Nanclares, and J. M. Marchetti, 2005: Sustained release of lidocaine from Poloxamer 407 gels. Int. J. Pharm. 288, 235-244.
17. Schmolka, J. R., 1972: Artificial Skin. I. Preparation and properties of Pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res. 6, 571-582.
18. Siefert, H. M., C. Kohlsdorfer, W. Steinke, and A. Witt, 1999: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J. Antimicrob. Chemother. 43(Suppl. B), 61-67.
19. Spreng, M., J. Deleforge, E. Thomas, B. Boisrame, and H. Drugeon, 1995: Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. J. Vet. Pharmacol. Ther. 18, 284-289.
20. Turnidge, J., 1999: Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs, 58, 29-36.
21. Wolfson, J. S., and D. C. Hooper, 1989: Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2, 378-424.
22. Zhang, L., D. L. Parsons, C. Navarre, and U. B. Kompella, 2002: Development and in-vitro evaluation of stained release Poloxamer 407 (P407) gel formulations of ceftiofur. J. Control Release 85, 73-81.